Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Famitinib - Jiangsu Hengrui Medicine

Next Previous
Drug Profile

Famitinib - Jiangsu Hengrui Medicine

Alternative Names: Famitinib maleate; SHR 1020

Latest Information Update: 06 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Diethylamines; Fluorobenzenes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor receptor antagonists; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Cervical cancer
  • Phase III Colorectal cancer; Gastrointestinal stromal tumours; HER2 negative breast cancer; Non-small cell lung cancer; Triple negative breast cancer
  • Phase II Biliary cancer; Endometrial cancer; Fallopian tube cancer; Nasopharyngeal cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Thyroid cancer; Urogenital cancer
  • Phase I/II Osteosarcoma
  • No development reported Fibroma

Most Recent Events

  • 29 May 2025 Registered for Cervical cancer (Second-line therapy or greater, Recurrent, Metastatic disease, Combination therapy) in China (PO, Capsule) - First Global Approval
  • 08 Apr 2025 Phase-III clinical trials in HER2-negative-breast-cancer (Combination therapy, Neoadjuvant therapy, First-line therapy) in China (PO) (NCT06913777)
  • 28 Dec 2024 No recent reports of development identified for clinical-Phase-Unknown development in Fibroma in China (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top